Results 221 to 230 of about 1,443,667 (357)

A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion. [PDF]

Virus Res
Xie C, Zhou B, Yao D, Wang X, Zhong L, Qiu C, Zhang J.   +6 more
europepmc   +1 more source

Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin [PDF]

, 2007
Dafne Müller, Anette Karle, Bettina Meißburger, Ines Höfig, Roland Stork, Roland E. Kontermann   +5 more
openalex   +1 more source

Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application

The FEBS Journal, EarlyView.
Multiple myeloma is characterised by the clonal proliferation of plasma cells in the bone marrow. Extracellular vesicles (EVs) are a key component of cell‐to‐cell communication within the bone marrow microenvironment, promoting tumour growth, bone remodelling, immune modulation, angiogenesis and therapeutic resistance.
Chloe Wylie, Rebecca Rowan, Dessi Malinova, Lisa Crawford   +3 more
wiley   +1 more source

Non-affinity platform for processing knob-into-hole bispecific antibody. [PDF]

Bioresour Bioprocess
Wang X, Li M, Li M, Hong H, Gao K, Zhao P.   +5 more
europepmc   +1 more source

Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95 [PDF]

, 2008
Tanja Herrmann, Ludger Große‐Hovest, Tina Otz, Peter H. Krammer, Hans‐Georg Rammensee, Gundram Jung   +5 more
openalex   +1 more source

Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics

Cellular & Molecular Immunology, 2020
Heliang Li, Phei Er Saw, E. Song
semanticscholar   +1 more source

Haemophilia Prophylaxis in the Age of Innovation: Exploring Opportunities for Personalized Treatment

Haemophilia, EarlyView.
ABSTRACT Introduction Recent advancements in haemophilia treatment have introduced a range of innovative therapies, including activated FVIII mimetics, ultra‐extended half‐life recombinant FVIII, rebalancing agents and gene therapy. These developments have transformed treatment options and expanded prophylaxis strategies.
Yesim Dargaud, Fabienne Volot, Stephanie Desage, Claire Pouplard, Valerie Chamouard, Anne Lienhart   +5 more
wiley   +1 more source

Taming interleukin-12: Engineering of bispecific antibody-based IL-12 mimetics with biased agonism capacities. [PDF]

Protein Sci
Lipinski B, Unmuth L, Arras P, Endruszeit R, Becker S, Rödel JM, Scheller J, Pudewell S, Floss DM, Krah S, Harwardt J, Doerner A, Helming L, Xu C, Menrad A, Evers A, Kolmar H, Elter D, Pekar L, Zielonka S.   +19 more
europepmc   +1 more source

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody [PDF]

, 2008
Shoshana Morecki, Horst Lindhofer, Elena Yacovlev, Yael Gelfand, Peter Ruf, Shimon Slavin   +5 more
openalex   +1 more source

Temporal trends in relative survival of diffuse large B‐cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies

British Journal of Haematology, EarlyView.
Sara Harrysson, Sandra Eloranta, Stefanie Antonilli, Mikkel Runason Simonsen, Kristina Sonnevi, Peter Brown, Bjorn E. Wahlin, Per‐Ola Andersson, Judit M. Jørgensen, Mats Jerkeman, Christian B. Poulsen, Gunilla Enblad, Tarec C. El‐Galaly, Karin E. Smedby   +13 more
wiley   +1 more source